April 6 @ 6-8p Eastern | Boston Marriott Cambridge
Traps to Avoid When Preparing for Commercial Launch
Preparing for commercial launch is a big deal for most companies. It requires strong leadership and coordination across many functional areas. There are also technical and regulatory hurdles. The company is investing significant efforts and capital before market approval is assured. These all dramatically raise the level of business risk.
Join us for an evening discussion of how to avoid the traps companies face most frequently when preparing for commercial launch:
- Starting your planning too late
- Building too much infrastructure too early
- Not taking into account possible scenarios that could change launch timing or key planning assumptions
- Ignoring preparations required to scale business processes and the organization
- Fragmented planning in functional silos
By preventing these pitfalls, you will reduce the risk of a launch delay and build closer coordination between the Technical Operations and Commercial/Market Access teams and other critical functional groups like Quality, Regulatory, Finance, and IT.
Date: April 6, 2023
Venue: Boston Marriott Cambridge, 50 Broadway Terrace, Cambridge, MA 02142
- 6-6:30p Food, Cocktails & Networking
- 6:30-7:30p Presentation & Discussion
- 7:30-8p Networking
President & CEO, Aeglea Therapeutics
Jeff Goldberg, MBA, is an accomplished biotech executive with 25+ years of experience leading teams from preclinical discovery through commercialization. Prior to Aeglea, Jeff served as president and CEO at Immunitas from 2019-2021. Under his leadership, Immunitas grew significantly, raised additional capital, and is now in the clinic with its first asset. Prior to Immunitas, Jeff served as the founding COO at Akcea. At Akcea, he was responsible for building functions and leading teams across all aspects of the business, eventually growing the team from two employees to 250+ in multiple geographies. He played a significant role in the company’s initial public offering and fundraising activities, business development and the global launch of two rare disease drugs. Earlier in his career, Jeff was the VP of business operations at Proteostasis Therapeutics, a rare disease company, and also held roles of increasing responsibility at Genzyme, where he led teams through product development and global launches across multiple therapeutic areas. Jeff has an M.B.A. and a M.S. in Chemical Engineering from the Massachusetts Institute of Technology, and a B.S. in Chemical Engineering from Cornell University.
Managing Director, Converge Consulting
Todd Applebaum has supported many clients transitioning from clinical development to commercial production of Biologics, Pharmaceuticals, and Cell Therapies. Todd consults on business strategy, manufacturing, technical operations, the quality system, process development, operational strategy & execution, supply chain management, business process/workflow automation and IT enterprise solutions. Prior to starting Converge Consulting, he served as VP, Technical Operations at Ovascience, Inc., helping transition the company from research to commercial operations. Todd also held the role of VP, Research for the Healthcare and Life Science industries at Gartner, Inc. where his research focused on building patient outcomes-focused operations, the impact of personalized and precision medicines, global operations and network planning, track & trace technologies and operational & performance excellence. He has a BS in Industrial Engineering from General Motors Institute and an MBA from Carnegie Mellon University.